APA (7th ed.) Citation

Michaeli, C. T., & Michaeli, D. (2024). Partial orphan cancer drugs: US food and drug administration approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending. Value in health, 27(4), . https://doi.org/10.1016/j.jval.2024.01.002

Chicago Style (17th ed.) Citation

Michaeli, Christoph T., and Daniel Michaeli. "Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending." Value in Health 27, no. 4 (2024). https://doi.org/10.1016/j.jval.2024.01.002.

MLA (9th ed.) Citation

Michaeli, Christoph T., and Daniel Michaeli. "Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending." Value in Health, vol. 27, no. 4, 2024, https://doi.org/10.1016/j.jval.2024.01.002.